Shareholder Update: May 4, 2023

Dear Valued Shareholders,

This is the news you’ve been waiting for.

Optimi Health today announced that it has entered into a $1.2 million CAD definitive supply agreement with a private entity focused on developing mushroom-based therapeutic drugs through pre-clinical research and clinical trials.

At this time, we are respecting the client’s wish to remain private and look forward to sharing more news on this exciting announcement at a future date and time.

Optimi will cultivate dried GMP psilocybin-containing biomass and extract it into a refined substance, which will be distributed to the client’s international research sites. This announcement affirms Optimi’s commitment to GMP production with capabilities to supply large scale, research and development programs.

“This is a big day for Optimi, and to be selected as the singular supply entity in the sector capable of scaling to help fulfill the needs of our client reflects our ability to deliver substantial value to the research community and our shareholders,” said Optimi CEO, Bill Ciprick.

This latest agreement has helped to fulfill the goal of Optimi Health’s Founders in making the company a true multinational participant in the research and development of psychedelic medicines.

Your ongoing support and belief in Optimi have helped us get to where we are today.

A copy of today’s press release can be found on our website at

Thank you.

Earnings Results

Optimi plans to report its Q2 2023 earnings results before markets open on a date soon to be approved (between May 19 – 30, 2023) by Optimi’s Audit Committee.

A complete End Of Year financial report will be made available on September 30, 2023, in order to provide a comprehensive picture of earnings from these ongoing agreements.

Questions related to this announcement should be directed to:

A New Face at Optimi:

We are pleased to announce that effective May 7, 2023, Karina Lahnakoski will be joining us full time as the “Director of Quality and Commercial Strategies”. In this newly created position, she will be responsible for overseeing the QA/QC functions for Optimi Labs Inc. and providing overall direction for Quality Management Systems to support the life cycle development of Optimi’s products.

In addition, Karina will be responsible for ensuring systems are in place for the testing and documentation of products manufactured, provide strategic direction, risk management, oversight, project management, and commercial planning for Optimi. As we begin to fully scale the operation, this will be a critical leadership role to keep us on track and GMP compliant with everything we do. Karina will assume a leadership role in coordinating efforts from production, labs and quality and will be an active member of leadership to report to Senior Leadership on operational progress.

Karina has a great background starting with a BSc. (Hons) in Biochemistry, is a certified Project Management Professional (PMP), ICD Certified (Institute of Corporate Directors) and a MBA from Schulich School of Business.




Investor Relations
Phone: +1 (902) 880 6121


Optimi Health Corp. is an end-to-end Canadian-based drug manufacturer and formulator licensed by Health Canada to produce and supply natural, GMP-grade psilocybin, synthetic psychedelic substances, and high-quality functional mushrooms that focus on the health and wellness markets. Built with the purpose of producing scalable psychedelic formulations for transformational human experiences, the Company’s goal is to be the number one trusted, compassionate supplier of safe drug products throughout the world. Optimi’s products are grown at its two facilities comprising a total of 20,000 square feet in Princeton, British Columbia.


Forward-Looking Statements This news release contains forward‐looking statements and forward‐looking information within the meaning of Canadian securities legislation (collectively, “forward‐looking statements”) that relate to Optimi’s current expectations and views of future events. Any statements that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance (often, but not always, through the use of words or phrases such as “will likely result,” “are expected to,” “expects,” “will continue,” “is anticipated,” “anticipates,” “believes,” “estimated,” “intends,” “plans,” “forecast,” “projection,” “strategy,” “objective,” and “outlook”) are not historical facts and may be forward‐looking statements and may involve estimates, assumptions and uncertainties which could cause actual results or outcomes to differ materially from those expressed in such forward‐looking statements. No assurance can be given that these expectations will prove to be correct and such forward‐looking statements included in this news release should not be unduly relied upon. These statements speak only as of the date of this news release. In particular and without limitation, this news release contains forward‐ looking statements pertaining to activities proposed to be conducted under the Company’s dealer’s license and associated business related to Psilocybin and Psilocin and Optimi’s plans, focus and objectives.

Forward‐looking statements are based on a number of assumptions and are subject to a number of risks and uncertainties, many of which are beyond Optimi’s control, which could cause actual results and events to differ materially from those that are disclosed in or implied by such forward‐looking statements. Such risks and uncertainties include, but are not limited to, the impact and progression of the COVID‐19 pandemic and other factors set forth under “Forward‐Looking Statements” and “Risk Factors” in the Company’s Annual information Form dated January 9, 2023, and other continuous disclosure filings available under Optimi’s profile at Optimi undertakes no obligation to update or revise any forward‐looking statements, whether as a result of new information, future events or otherwise, except as may be required by law. New factors emerge from time to time, and it is not possible for Optimi to predict all of them or assess the impact of each such factor or the extent to which any factor, or combination of factors, may cause results to differ materially from those contained in any forward‐looking statement.

Any forward‐looking statements contained in this news release are expressly qualified in their entirety by this cautionary statement.


Investor Relations
Phone: +1 (902) 880 6121


Products do not contain psilocybin

Get news & updates directly to your inbox.
Interested In Optimi? Let's Talk.